INS and type 2 diabetes mellitus: Indeed, studies in animals and humans with type 2 diabetes showed that oral administration of DCAs (sebacic acid) improved glycemic control, probably by enhancing insulin sensitivity, and reduced hepatic gluconeogenesis and glucose output (Iaconelli et al., 2010).